![Yoshihiro Otaki](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Yoshihiro Otaki
Presidente presso BioFrontier Partners, Inc.
Posizioni attive di Yoshihiro Otaki
Società | Posizione | Inizio | Fine |
---|---|---|---|
BioFrontier Partners, Inc.
![]() BioFrontier Partners, Inc. Investment ManagersFinance BioFrontier Partners Inc (BioFrontier Partners) is a venture capital firm founded in 2000. The firm is headquartered in Tokyo, Japan. | Presidente | 10/03/1999 | - |
GeneCare Research Institute Co., Ltd.
![]() GeneCare Research Institute Co., Ltd. Medical/Nursing ServicesHealth Services GeneCare Research Institute Co., Ltd. engages in the research, development, and drug discovery of treatments in the field of cancer, inflammation, hepatic carcinoma and rheumatism. It provides the distribution services for its products through their direct customers, which includes pharmaceutical companies and clinical-related companies. The company was founded by Yasuhiro Furuichi on December 20, 2000 and is headquartered in Kamakura, Japan. | Direttore/Membro del Consiglio | 20/12/2000 | - |
Healthcare Innovation Co. Ltd.
![]() Healthcare Innovation Co. Ltd. Investment ManagersFinance Healthcare Innovation Co. Ltd. (Healthcare Innovation) is a Venture Capital firm founded in 2017. The firm is headquartered in Tokyo, Japan. | Presidente | - | - |
Cell-Medicine, Inc.
![]() Cell-Medicine, Inc. Pharmaceuticals: MajorHealth Technology Cell-Medicine, Inc. is a Japanese company that specializes in cancer immunotherapy based on scientific evidence. The private company is based in Tsukuba, Japan. The company aims to prevent the recurrence of cancer after surgery, prevent metastasis, and treat remaining cancer. The company's self-cancer vaccine therapy is based on scientific evidence and is designed to target recurring and metastasizing cancer after surgery, as well as treat remaining cancer. The company was founded in 2001 by Tadao Ono. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Yoshihiro Otaki
Precedenti posizioni note di Yoshihiro Otaki
Società | Posizione | Inizio | Fine |
---|---|---|---|
HUMAN METABOLOME TECHNOLOGIES, INC. | Presidente | 01/07/2003 | - |
Fondatore | 01/07/2003 | - |
Formazione di Yoshihiro Otaki
Tohoku University | Doctorate Degree |
Statistiche
Distribuzione geografica
Giappone | 7 |
Posizioni
Chairman | 2 |
Director/Board Member | 2 |
President | 1 |
Settori
Finance | 3 |
Health Technology | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
HUMAN METABOLOME TECHNOLOGIES, INC. | Health Technology |
Aziende private | 4 |
---|---|
BioFrontier Partners, Inc.
![]() BioFrontier Partners, Inc. Investment ManagersFinance BioFrontier Partners Inc (BioFrontier Partners) is a venture capital firm founded in 2000. The firm is headquartered in Tokyo, Japan. | Finance |
GeneCare Research Institute Co., Ltd.
![]() GeneCare Research Institute Co., Ltd. Medical/Nursing ServicesHealth Services GeneCare Research Institute Co., Ltd. engages in the research, development, and drug discovery of treatments in the field of cancer, inflammation, hepatic carcinoma and rheumatism. It provides the distribution services for its products through their direct customers, which includes pharmaceutical companies and clinical-related companies. The company was founded by Yasuhiro Furuichi on December 20, 2000 and is headquartered in Kamakura, Japan. | Health Services |
Healthcare Innovation Co. Ltd.
![]() Healthcare Innovation Co. Ltd. Investment ManagersFinance Healthcare Innovation Co. Ltd. (Healthcare Innovation) is a Venture Capital firm founded in 2017. The firm is headquartered in Tokyo, Japan. | Finance |
Cell-Medicine, Inc.
![]() Cell-Medicine, Inc. Pharmaceuticals: MajorHealth Technology Cell-Medicine, Inc. is a Japanese company that specializes in cancer immunotherapy based on scientific evidence. The private company is based in Tsukuba, Japan. The company aims to prevent the recurrence of cancer after surgery, prevent metastasis, and treat remaining cancer. The company's self-cancer vaccine therapy is based on scientific evidence and is designed to target recurring and metastasizing cancer after surgery, as well as treat remaining cancer. The company was founded in 2001 by Tadao Ono. | Health Technology |
- Borsa valori
- Insiders
- Yoshihiro Otaki
- Esperienza